Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
11 déc. 2017 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma ...
Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
11 déc. 2017 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma ...
Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate
13 nov. 2017 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate ~ Data shows a 73% one-year...
Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate
13 nov. 2017 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate ~ Data shows a 73% one-year survival...
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
31 oct. 2017 08h01 HE
|
Immunocore Limited
PRESS RELEASE Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (Oxford, UK and...
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
31 oct. 2017 03h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (Oxford, UK and Conshohocken,...
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
04 oct. 2017 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, US, 4 October 2017) Immunocore Limited, the world's leading TCR company...
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
04 oct. 2017 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, US, 4 October 2017) Immunocore Limited, the world's leading TCR company developing...
Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases
18 sept. 2017 07h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases $40 million investment to accelerate development of...
Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline
03 juil. 2017 02h00 HE
|
Immunocore Limited
PRESS RELEASE Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline (Oxford, UK and Conshocken, US, 3 July 2017) Immunocore Limited, the...